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Ex Vivo Tracer Efficacy in Optical 
Imaging of Staphylococcus Aureus 
Nuclease Activity
Colin W. K. Rosman1,2,3, Francisco Romero Pastrana1, Girbe Buist1, Marjolein Heuker1, 
Marleen van Oosten1, James O. McNamara4, Gooitzen M. van Dam2 & Jan Maarten van Dijl1
The key to effective treatment of bacterial infections is a swift and reliable diagnosis. Current clinical 
standards of bacterial diagnosis are slow and laborious. There are several anatomical imaging 
modalities that can detect inflammation, but none can distinguish between bacterial and sterile 
inflammation. Novel tracers such as smart activatable fluorescent probes represent a promising 
development that allow fast and specific testing without the use of ionizing radiation. Previously, a 
smart activatable probe was developed that is a substrate for the micrococcal nuclease as produced 
by Staphylococcus aureus. In the present study, the function of this probe was validated. Practical 
applicability in terms of sensitivity was assessed by incubation of the probe with 26 clinical S. aureus 
isolates, and probe specificity was verified by incubation with 30 clinical isolates and laboratory strains 
of various bacterial pathogens. The results show that the nuclease-specific probe was activated by all 
tested S. aureus isolates and laboratory strains with a threshold of ~106–107 cells/mL. The probe was 
also activated by certain opportunistic staphylococci. We therefore propose that the studied nuclease 
probe represents a significant step forward to address the need for a rapid, practical, and precise 
method to detect infections caused by S. aureus.
Bacterial infections are a serious clinical problem in all fields of modern medicine. Staphylococcus aureus is one of 
the largest contributors to in-hospital infections, causing 19.5% of all surgical site infections (SSI’s), 14.6% of all 
Intensive Care Unit (ICU)-acquired pneumonia episodes and 10.1% of all ICU-acquired bloodstream infections 
in the European Union1. What makes this particular pathogen so dangerous is the rapid acquisition of resistance 
and the ability to form biofilms. S. aureus infections, and especially methicillin-resistant S. aureus (MRSA), are 
hard to treat because of these properties. In 2014, 46.4% of all S. aureus associated with ICU-acquired infections 
were MRSA1.
The most common sites of infection for S. aureus are catheters, prosthetic devices and SSI’s2. SSI and infection 
of prosthetic devices are especially difficult to treat once biofilm formation has started. S. aureus is also a major 
cause of many focal bacterial infections, such as osteomyelitis3, septic arthritis4, and pyomyositis5. What makes 
the treatment of these infections even more challenging is that these patients are often old, morbid and stationary.
The current diagnostic standards are based on sample collection by, respectively, performing a biopsy or swab-
bing the affected area and culturing these samples. Downsides of both approaches are the amount of time and 
labor it takes to reach a reliable diagnosis, and the possible harm to the patient6,7. Moreover, the different diagnos-
tic techniques are prone to false-negative results8. Importantly, focal bacterial infections can be life-threatening, 
while current diagnostic procedures typically take hours to days, which gives rise to higher hospital costs and 
patient dissatisfaction.
Other ways of detecting infections are the use of anatomical imaging modalities, such as ultrasound, computed 
tomography (CT) or magnetic resonance imaging (MRI), or functional imaging modalities, such as positron 
emission tomography (PET), single photon emission computed tomography (SPECT) or scintigraphy9,10. These 
techniques allow detection in the whole body and are noninvasive. However, none of these imaging modalities 
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can discriminate a bacterial inflammation from a sterile inflammation, nor can they give any information about 
the type of pathogen11–14.
In recent years, multiple researchers have proposed techniques to improve these imaging modalities by using a 
wide array of probes and suggesting new imaging modalities15. Promising new imaging techniques are fluorescent 
imaging and photoacoustic tomography (PAT)16. These techniques do not require any form of ionizing radiation 
like CT, MRI, PET, SPECT and scintigraphy. They can also be used relatively easily in the operating theatre. The 
main advantage of PAT is that the optical scattering is bypassed by using soundwaves15. However, before it can be 
used in the clinic both the PAT capabilities and probe functionality have to be improved17.
To be able to distinguish between sterile inflammation and bacterial infections various probes have been 
designed that specifically target bacteria. Examples are tracers linked to antibiotics, such as vancomycin18, or sug-
ars that are solely metabolized by bacteria, such as sorbitol19 and maltose20,21. These types of tracers do not allow 
identification of a specific pathogen, but give an indication of the type of bacteria causing infection. An even more 
specific approach involves the use of fluorescently labeled antibodies or nanobodies. In general, it takes approx-
imately 4–6 days for antibodies to reach the optimal target to normal tissue (T/N) ratio, which makes the use of 
antibodies less practical when rapid diagnosis is needed22. Researchers have developed nanobodies that reach the 
optimal T/N ratio in several hours to overcome this problem23. First results look promising, though much more 
extensive research is needed to safeguard the function after binding to imaging agents and reduce clearance23.
A review on biomarkers in wound infections has been published recently24. The authors of this article con-
cluded that there is an urgent need for novel diagnostic tools in wound infection. There are multiple promising 
discoveries in this field of research, though it seems that the rapid diagnostic techniques still lack specificity and 
the specific diagnostic techniques are laborious and time-consuming.
Smart activatable probes represent a highly innovative development. After activation, these probes emit a 
different signal from their default state. By determining the T/N ratio the accuracy of the measurements can be 
vastly improved25,26. Degradative enzymes make optimal targets for this type of probe. A promising enzyme is the 
micrococcal nuclease, which is a DNA-degrading enzyme of which many different types of bacteria express their 
own, type-specific version27. In particular, Hernandez et al. have reported a nuclease-activated probe that reacted 
specifically to Staphylococcal nuclease28. This so-called ‘TT-probe’ consisted of a fluorophore and a quencher that 
are connected by a short, 11-base, oligonucleotide. Specifically, the TT-probe used fluorescein amidite (FAM) as a 
fluorophore, 2 deoxythymidine nucleotides flanked by several 2′-O-methyl modified nucleotides as oligonucleo-
tide and the ZEN and Iowa Black RQ quenchers of Integrated DNA Technologies (IDT). For in vivo experiments 
the FAM was replaced by Cy5.5. The latter probe allowed the detection of a focal S. aureus infection within 1 hour 
in vitro and 1–2 hours in mice.
The present study was aimed at validating the function and determining the potential for clinical application 
of the nuclease-activated P2&3 TT-probe. The P2&3 TT-probe is a derivative of the original TT-probe28 in which 
the unmodified TT dinucleotide is placed at nucleotide positions 2 and 3 of the 11-nucleotide-long oligonucle-
otide (versus positions 5 and 6 in the original TT-probe). This probe derivative was found to yield greater sensi-
tivity for micrococcal nuclease of S. aureus than the original TT-probe (McNamara lab, unpublished data). We 
focused on verification of the working mechanism, probe stability in human blood, sensitivity and specificity in 
a clinical setting. The specificity and sensitivity were determined using clinical isolates of S. aureus and related 
bacterial species.
Results
Probe activation by secreted nuclease. The P2&3 TT-probe was incubated with 3 different S. aureus 
Newman strains, namely the wild-type, a Δnuc mutant and a Δnuc Δnuc2 double mutant. Correction of back-
ground was based on the negative control and normalization was based on the positive control. As shown in 
Fig. 1, probe activation was almost solely dependent on secreted nuclease. Incubation of the Newman wild-type 
strain with the P2&3 TT-probe resulted in a mean fluorescence intensity of 1.115(sD 0.448), incubation of the 
Δnuc mutant in a mean fluorescence intensity of 0.0421(sD 0.088), and the Δnuc Δnuc2 double mutant in a 
mean fluorescence intensity of −0.251 (sD 0.038). After incubation both nuclease mutants showed statistically 
different probe activation levels compared to the wildtype (P < 0,0001, P < 0,0001). Probe activation was not 
statistically different in both mutants.
Probe stability in human blood and plasma. Incubation of the P2&3 TT-probe in human plasma or 
human blood did not result in probe activation. In contrast, incubation of the probe in human plasma or blood 
with purified nuclease resulted in activation of the probe (Fig. 2). Correction of background was based on the 
negative control and normalization was based on the positive control. Incubation of plasma without nuclease 
resulted in a fluorescence intensity of 0.076 (sD 0.000), plasma with nuclease in a fluorescence intensity of 0.969 
(sD 0.015), blood without nuclease in a fluorescence intensity of 0.035 (sD 0.002), and blood with nuclease in a 
fluorescence intensity of 0.436 (sD 0.058). Incubations with nuclease were statistically different from incubations 
without nuclease (plasma P < 0.0001; blood P < 0.001). Importantly, a significant difference in P2&3 TT-probe 
activation between incubations of plasma and blood with nuclease was observed (P < 0.0001). No statistical dif-
ference between incubations of plasma or blood without nuclease was found. The lower fluorescence intensity of 
activated probe in blood was expected due to overlap in the absorption spectrum of hemoglobin and the emission 
spectrum of FITC.
Sensitivity of the nuclease probe. 26 clinical S. aureus isolates were incubated with the P2&3 TT-probe 
in triplicate. Correction of background was again based on the negative control and normalization on the positive 
control. The mean normalized fluorescence intensity was 0.86 (sD 0.43). The cutoff for a positive reaction was 
set at 43% of the positive control signal. This cutoff point represents the mean activation minus one standard 
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deviation and covers all tested S. aureus strains (Fig. 3). Of note, a large heterogeneity in probe activation was 
detected. This corresponds with the heterogeneity observed in nuclease production as documented in a previous 
study where the exoproteomes of 25 of the presently tested clinical S. aureus isolates were characterized29.
For validation of P2&3 TT-probe activation by different amounts of bacteria or by bacteria grown to different 
growth stages, we measured the nuclease activity of four S. aureus strains. These included S. aureus Newman 
wild-type, the nuclease-deficient Δnuc mutant, and the clinical isolates X and U. The two clinical isolates were 
chosen, because of their differing nuclease production levels and different clinical backgrounds. Isolate X is 
a high-level nuclease producer that was collected from the throat of a patient with cholangitis9. Isolate U is a 
low-level nuclease producer that was collected from the blood of a patient with sepsis, meningitis, and probably 
Figure 1. P2&3 TT-probe activation by S. aureus Newman (Newman), S. aureus Newman Δnuc (Δnuc) 
and S. aureus Newman Δnuc, Δnuc2 (Δnuc, Δnuc2). The horizontal line represents the mean. ***Indicates 
P < 0.0001.
Figure 2. Normalized fluorescence intensity after probe incubation in human blood and plasma. Horizontal 
line represents the mean. –indicated no nuclease was added. +indicates nuclease was added. **Indicates 
P < 0.001, ***indicates P < 0.0001.
Figure 3. Normalized fluorescence intensity after incubation of clinical S. aureus isolates. A/Z indicate the 
isolates that were incubated. The dotted horizontal line represents the positive cutoff. Bars indicate mean 
fluorescence. Capped lines indicate standard deviation.
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endocarditis9. All bacteria were grown in tryptic soy broth (TSB) and Roswell Park Memorial Institute medium 
(RPMI). Of note, the RPMI 1640 was used to grow S. aureus, because the global gene expression patterns of S. 
aureus cells grown in RPMI or human plasma were recently shown to be highly similar30. At T = 0, 3, 6, 12, and 
24 hours, the colony-forming units (CFU) per mL and nuclease activity were measured (Fig. 4). All strains grew 
more abundantly in TSB than in RPMI medium. As shown in Fig. 4, the wild-type Newman strain showed an 
increase in nuclease activity upon entering the stationary growth phase, while no nuclease activity was detectable 
for the isogenic Δnuc mutant. As expected, isolate X showed significant nuclease production in the late expo-
nential and stationary growth phases (Fig. 4C). In contrast, isolate U showed significant nuclease activity during 
growth in TSB, but it did not show any nuclease activity whilst growing in RPMI medium. With exception of 
this specific condition, and the nuclease deficient mutant, all strains activated the probe above the threshold at 
106−107 CFU/mL, regardless of the growth medium used. Essentially the same results were obtained when the 
nuclease activity in the samples was measured with the so-called poly T probe (Supplemental Fig. 1). This poly 
T probe consists of the same fluorophore and quencher as the P2&3 TT probe, but the connecting oligonucle-
otide consists of 11 unmodified thymine bases31. This results in a higher sensitivity for nuclease activity which 
enables detection of the lower level of nuclease in isolate U when it is grown in RPMI, but lowers the specificity to 
Staphylococcal nuclease as the poly T probe can be degraded by many different endonucleases28.
Specificity of the nuclease probe. To verify specificity of the P2&3 TT-probe, thirty different bacterial 
isolates were incubated with this probe. These included two S. aureus laboratory strains (Newman and RN4220), 
four non-staphylococcal laboratory strains (Bacillus subtilis 168, E. coli DH5α, Staphylococcus epidermidis 
ATCC 35984 and S. epidermidis 1457), and a total of 24 clinical isolates of 12 different species (see Materials 
and Methods). Abiding by the cutoff point that was previously determined, eight bacterial isolates tested pos-
itive for nuclease activity. These were S. aureus Newman, S. aureus RN4220, Staphylococcus lugdunensis 1 and 
2, Staphylococcus caprae, Staphylococcus capitis 1 and 2, and B. subtilis 168 (Fig. 5A). The 22 other strains tested 
negative with values lower than the cutoff point (Fig. 5B).
Discussion
The objective of this research was to validate the function of the nuclease-activated P2&3 TT-probe, an optimized 
version of the probe described by Hernandez et al.28, and to assess its ex vivo efficacy in optical imaging of S. 
aureus infections. All incubations were done in 1 hour, demonstrating the swiftness of the process. As expected, 
the P2&3 TT-probe was activated by secreted nuclease of S. aureus. The probe proved to be stable enough to 
maintain its function in both human plasma and blood. The P2&3 TT-probe was also shown to be activated upon 
incubation with a wide variety of clinical S. aureus isolates for the first time. Apart from S. aureus, incubation with 
four other staphylococcal species also resulted in activation of the probe.
The P2&3 TT-probe was shown to be stable in both human blood and human plasma. However, the signal 
strength was much lower in human blood than in plasma. This is probably caused by the overlap of the FITC label 
emission spectrum (521 nm) and the absorption spectrum of hemoglobin32. Nevertheless, in vitro absorption 
of the P2&3 TT-probe’s fluorescence does not have to pose a problem, as long as the normalization standard is 
subject to the same degree of absorption. For in vivo use, or use in an assay that includes hemoglobin a differ-
ent fluorophore will have to be used. For example, imaging in vivo with a Cy5 fluorophore instead of FITC was 
already done by Hernandez et al.28.
Figure 4. Activation of the P2&3 TT-probe by S. aureus grown to different stages in TSB and RPMI. Left Y-axis 
and lines in black indicate CFU per mL, right Y-axis and lines in red indicate probe activation as a percentage of 
the maximum activation. All experiments were done in triplicate, and the plots present the average numbers of 
the measurements. Capped lines indicate standard deviation. Strains included were: A, S. aureus Newman wild-
type; B, nuclease deficient S. aureus mutant (Δnuc); C, S. aureus clinical isolate X29; and D, S. aureus clinical 
isolate U29.
www.nature.com/scientificreports/
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The clinical S. aureus isolates tested are representative for the diversity of S. aureus that can be encountered 
in a clinical setting, in our case the University Medical Center Groningen. Our results thus show that the probe 
is an effective tool to detect the presence of such different S. aureus isolates. The signal strength observed in the 
different S. aureus incubations showed a great heterogeneity, as was to be expected based on previous proteome 
analyses that had shown variety in the levels of nuclease produced by different clinical S. aureus isolates29. This 
heterogeneity implies that nuclease production, and therefore probe activation, is likely to be different for every 
S. aureus strain.
Three of the four non-S. aureus species that tested positive are regarded as harmless, being soil bacteria (B. 
subtilis) and non-pathogenic human commensals (S. capitis and S. caprae). The fourth bacterium that tested posi-
tive is S. lugdunensis. This species is regarded as a true pathogen and has been implicated in infections reminiscent 
of S. aureus infections33. Activation of the TT-probe by S. lugdunensis was also reported by Hernandez et al.28. 
We note that Hernandez et al. and Brakstad et al. 1995 found relatively lower levels of nuclease activity produced 
by S. lugdunensis (Hernandez et al.), S. capitis (Brakstad et al.) and S. caprae (Brakstad et al.) as compared to S. 
aureus34. As most of the signals in the positives of Fig. 5A are essentially saturated, it is difficult to derive relative 
levels of nuclease activity from these samples. Our results are thus not inconsistent with these previous reports. 
Of note, all tested bacterial species that can cause infection gave a positive signal with the probe, while bacterial 
species that produce non-micrococcal nucleases did not activate the probe. This indicates that the tested P2&3 
TT-probe has a high application potential in a clinical-diagnostic setting. One concern could be that mutations in 
the nuclease-encoding gene could cause a diagnostic resistance. To date, there has been no large investigation on 
the possible occurrence of nuclease-deficient S. aureus in the clinic. However, nuclease plays an important role in 
Figure 5. P2&3 TT-probe activiation by different bacterial isolates. (A) Normalized fluorescense intensity upon 
P2&3 TT-probe activation by of all strains that tested positive. B. subtilis was grown in LB and the respective 
measurements were normalized with LB controls. All other strains were grown in TSB. (B) normalized 
fluorescence intensity of strains that tested negative with the P2&3 TT-probe. E. coli was grown in LB and the 
respective measurements were normalized with LB controls. All other strains were grown in TSB.
www.nature.com/scientificreports/
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S. aureus biofilm dynamics and has been widely used as a specific marker for S. aureus. Thus, it seems unlikely that 
spontaneous nuclease mutations will occur. Two other conceivable complications are (i) that it is not precisely 
known how nuclease production is influenced by random mutations that can be encountered in a clinical setting, 
or (ii) what influence different growth conditions may have on nuclease production. The lack of P2&3 TT-probe 
activation by the clinical S. aureus isolate U grown in RMPI medium is an example of the latter possibility. Here, 
it should be noted that isolate U is the clinical isolate with the lowest nuclease production levels in our collection.
Altogether, our present observations support the view that smart-activatable probes are a promising develop-
ment towards rapid, robust, sensitive and specific diagnostic and imaging tools. Importantly, the presently studied 
P2&3 TT-probe allows for specific in vivo imaging of nucleases produced by pathogenic staphylococci without 
the use of ionizing radiation. Future use of this probe could be in clinical diagnostic tools or in the context of an 
imaging modality. Clinical applications may include the identification of S. aureus on patient material (like skin 
or bodily fluids), material that has been in contact with patients (like bandages, prosthetics or catheters) or even 
in vivo imaging during and after surgery. Additional research will be needed to investigate all possible future 
applications.
Materials and Methods
Bacterial lab strains and clinical isolates. The S. aureus Newman nuclease mutants were a gift from Dr. 
Alexander Horswill, Department of Microbiology, Roy J. and Lucille A. Carver College of Medicine, University of 
Iowa (USA). The clinical strains were collected at the Department Medical Microbiology (bacterial diagnostics) 
in the University Medical Center Groningen (UMCG) and coded to ensure patient privacy. Clinical S. aureus 
isolates (n = 26) are coded with a letter. Isolates A/Y were collected in a previous study29. Isolate Z was collected 
later. The other clinical strains are shown as species and number. This number is used to differentiate between 
independent isolates of the same species. These include S. epidermidis (epi 1–6), Staphylococcus hominis (hom 
1–3), Staphylococcus haemolyticus (haem 1–2), Staphylococcus pasteuri (pas 1–2), Staphylococcus warneri (war 
1–2), Staphylococcus saprophyticus (sap 1–2), S. lugdunensis (lug 1–2), S. capitis (capi 1–2), S. caprae (caprae), 
Staphylococcus pettenkoferi (pet) and Streptococcus pyogenes (pyo). The laboratory strains used were: B. subtilis 
168, S. aureus Newman35, S. aureus RN4220, Escherichia coli DH5α, S. epidermidis American type culture col-
lection (ATCC) 35984 and S. epidermidis 1457. Before use all bacterial strains were stored at −80 °C in a 10% 
glycerol suspension.
Growth media. All bacteria were cultured by plating on a blood agar with 5% sheep blood (BA; Media 
Products B.V., Groningen, the Netherlands). After plating the bacteria were incubated overnight in a stove at 
37 °C. Then one colony was resuspended in a round bottom 96-well plate with 200 µL growth medium. B. subtilis 
and E. coli were grown in Lysogeny Broth (LB; BD Biosciences, Sparks, MD). All other bacteria were grown in 
TSB (BD Biosciences, Sparks, MD). After inoculation, the 96-wells plate was placed in an orbital shaker-incubator 
and incubated for 1 hour at 37 °C at 800 rpm. RPMI 1640 medium was supplemented with 2 mM glutamine (GE 
Healthcare/PAA, Little Chalfont, United Kingdom).
Nuclease-probe. The nuclease-activated P2&3 TT-probe was developed in the McNamara lab of the 
Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa (USA) as 
previously described28. The probe was synthesized and HPLC purified by Integrated DNA Technologies (IDT) 
of Coralville, IA. The probe consists of the following: 5′-FAM-mU T T mU mU mU mU mU mU mU mU –
ZEN-RQ-3′, where FAM is fluorescein amidite, mU is 2′-O-methyl modified U, T is unmodified deoxythymidine, 
ZEN is the ZEN quencher and RQ is the Iowa Black RQ quencher. The lyophilized probe was dissolved in 10 mM 
Tris-HCl pH 8.0, 1 mM EDTA to a final concentration of 500 µM and stored at −20 °C. For nuclease assays, 9 µL 
of 10 mM Tris-HCl pH 9.0, 10 mM CaCl2 was added to 1 µL 500 µM probe to yield the probe working stock. For 
reactions, 1 µL probe working stock was added to 9 µL substrate. Growth medium with added nuclease was used 
as negative control. For positive controls 1 µL purified nuclease (10 U/mL) was added. The reactions were incu-
bated for 1 hour at 37 °C. Then 290 µL of 10 mM Tris-HCl pH 9.0, 10 mM EDTA was added to stop the activity of 
micrococcal nuclease by binding the free Ca2+ ions which are needed for nuclease activity. 95 µL of each stopped 
reaction was transferred to each of 3 wells of a flat bottomed 96-well plate and FITC fluorescence was measured.
Reagents. TSB was prepared by dissolving 40 g Oxoid tryptone soya broth (CM0129) in 1 L purified water. LB 
was prepared by dissolving 25 g of Difuco LB Broth, Miller (Luria-Bertani) in 1 L of purified water. Recombinant 
micrococcal nuclease was purified from Lactococcus lactis as previously described36. Blood was donated by a 
healthy volunteer and stored in a BD Vacutainer® Blood Collection Sodium Citrate Tube, 0.105 M / 3.2%. Plasma 
was obtained by centrifuging the blood for 1 minute at 14000 rpm and extracting the plasma.
Fluorescence measurements. All fluorescence levels were measured using a Biotek synergy 2.0 plate 
reader unless stated otherwise. Fluorescence was measured with filters optimal for FITC. Optics position was set 
at ‘bottom’ and sensitivity at 35.
Nuclease activity and statistical analyses. Except where stated otherwise, the calculation of nuclease 
activity was carried out as follows. Mean fluorescence levels of negative control were subtracted prior to normali-
zations to correct for background interference. All data was normalized based on the mean positive control value. 
Normalization was based on the mean fluorescence of the positive control. Except where stated otherwise all incu-
bations were executed in triplicate. All p-values were calculated using a Student’s t-test in IBM SPSS statistics 22.
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Secreted and cell wall-bound nuclease assay. To determine the effect of secreted and cell wall-bound 
nuclease on the nuclease probe activation, three varieties of S. aureus Newman were used, namely the wild-type 
strain, a Δnuc mutant and a Δnuc Δnuc2 double mutant. The expression of the nuc gene leads to secretion of 
active nuclease. Expression of the nuc2 gene leads to expression of a cell wall-bound nuclease37. Probe incubated 
in TSB was used as negative control. Probe incubated in TSB plus purified recombinant nuclease were used as 
positive controls.
Blood interference assay. To determine the effect of whole blood and plasma on the probe, the probe was 
suspended in either plasma or whole blood. From each suspension two samples were withdrawn and one sample 
was incubated with purified nuclease and one sample without. Probe incubated in PBS was used as a negative 
control and used to correct for background interference. Probe incubated in PBS and purified nuclease was used 
as positive control. After terminating the reaction, nuclease activity in the suspension was measured in triplicate.
Sensitivity and specificity assays. To determine the sensitivity and specificity of the probe, all strains 
were grown on BA plates and 1 colony was incubated with the nuclease probe per protocol and subsequently 
imaged. Incubations were performed in triplicate. Negative controls were included in the analysis by incubating 
the probe in TSB or LB, while for positive controls purified nuclease was added to the TSB or LB. Correction for 
background was done using the negative controls in TSB or LB, depending on which growth medium was used 
to culture the bacteria. Normalization was performed based on the positive control in TSB or LB, depending on 
which growth medium was used to culture the bacteria.
For the growth curves, strains were cultured overnight in TSB, then washed 3 times with PBS. Optical Density 
(OD) was measured at 600 nm and all strains were resuspended at 0,0001 OD600 in TSB or RPMI 1640. After 0, 
3, 6, 12, and 24 h of incubation, CFU were determined through serial dilution and plating in triplicate. Samples 
were collected and stored at −80 °C for subsequent nuclease activity measurements. This experiment was done 
three times.
Ethical approval. The Independent Ethics Committee of the Foundation ‘Evaluation of Ethics in Biomedical 
Research’ (Assen, the Netherlands), approved the protocol for blood donations from healthy volunteers. This 
protocol is registered by QPS Groningen (code 04132-CS011). All volunteers provided their written informed 
consent. The study was performed with adherence to the guidelines of the Declaration of Helsinki and local reg-
ulations, and all samples were anonymized.
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